APVO436

BIOLOGICAL3 trials

Sponsors

Aptevo Research and Development LLC, Aptevo Therapeutics

Conditions

AMLAcute Myeloid Leukemia (AML)MDS

Phase 1

Study of APVO436 in Patients With AML or MDS

Aptevo Research and Development LLCAML, MDS

Start: 2018-12-13End: 2023-06-15Target: 136Updated: 2022-02-10

Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

WithdrawnNCT04973618

Aptevo TherapeuticsAML

Start: 2025-01-31End: 2027-01-31Updated: 2021-12-01

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

RecruitingNCT06634394

Aptevo TherapeuticsAcute Myeloid Leukemia (AML)

Start: 2024-10-01End: 2028-03-31Target: 39Updated: 2025-05-11

Related Papers

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood2022-11-1516 citations

Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS

Blood2021-11-054 citations

Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Blood2021-11-051 citations

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Cancers2021-10-218 citations

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood2020-11-0411 citations